A Tolerability and Pharmacokinetics Phase 1 Study of SHR6390 in Advanced Melanoma Patients
Phase of Trial: Phase I
Latest Information Update: 14 Apr 2016
At a glance
- Drugs SHR 6390 (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- Sponsors Jiangsu Hengrui Medicine Co.
- 11 Apr 2016 Status changed from not yet recruiting to recruiting.
- 20 Feb 2016 New trial record